Aracely Janneth Naranjo Viteri

Ms. Aracely Janneth Naranjo Viteri

Instituto de Farmacología Experimental de Córdoba, CONICET, Córdoba, Argentina
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2025 in Plants
Verified
Journal Article
Open access
PDF file
MCMatías Jávega Cometto
Matías Jávega Cometto
Aracely Janneth Naranjo ViteriAracely Janneth Naranjo Viteri
Aracely Janneth Naranjo Viteri
LCLeandro Gabriel Champarini
Leandro Gabriel Champarini
CHClaudia Hereñu
Claudia Hereñu
Rosana CrespoRosana Crespo
Rosana Crespo
Monoterpenes (MTs) are plants’ secondary metabolites and major components of essential oils (EOs), widely used in the pharmaceutical industry. However, its neuroprotective effects, particularly in Parkinson’s disease (PD) have not been fully demonstrated. PD is a progressive neurological disorder marked by dopaminergic neuron loss in the substantia nigra, motor symptoms being the most reported ones. This review evaluates the evidence supporting the use of MTs as potential neuroprotective agents. PubMed, SCOPUS, Google Scholar, and ScienceDirect databases were searched for articles on MTs in murine models with any type of administration. The PRISMA guidelines were followed. After screening 405 records, 32 were included in the systematic review and 30 were included in the meta-analysis. Fifteen MTs, commonly found in EOs, were identified as potential therapeutic agents for PD. The meta-analysis revealed that MTs administration improved motor performance, increased tyrosine hydroxylase levels, reduced oxidative stress markers (malondialdehyde) and proinflammatory cytokines (IL-6, IL-1, TNF-α), and enhanced antioxidant enzymes (catalase, superoxide dismutase) in parkinsonian animals. The antioxidant and anti-inflammatory properties of MTs appear to be key mechanisms in mitigating dopaminergic neurodegeneration. However, further clinical research is essential to translate these findings into practical applications.

4 February 2025 in Pharmacological Research - Modern Chinese Medicine
Verified
Journal Article
Open access
Aracely Janneth Naranjo ViteriAracely Janneth Naranjo Viteri
Aracely Janneth Naranjo Viteri
MCMatías Jávega Cometto
Matías Jávega Cometto
MCMatías Caverzan
Matías Caverzan
LCLeandro Gabriel Champarini
Leandro Gabriel Champarini
MZMaría Paula Zunino
María Paula Zunino
RCRosana Crespo
Rosana Crespo

4 May 2026 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
LCLeandro Gabriel Champarini
Leandro Gabriel Champarini
MHMacarena Lorena Herrera
Macarena Lorena Herrera
MCMatías Jávega Cometto
Matías Jávega Cometto
RBRocío del Valle Bartolozzi
Rocío del Valle Bartolozzi
Aracely Janneth Naranjo ViteriAracely Janneth Naranjo Viteri
Aracely Janneth Naranjo Viteri
CHClaudia Hereñu
Claudia Hereñu
Background: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons, leading to a spectrum of motor and non-motor symptoms. In addition to the motor deficits serving as the primary criteria for diagnosis, mood and anxiety disorders also play a significant role in shaping the prognosis and overall disease progression in PD. Objectives: In this study, our aim was to characterize the progression of anxiety-like behavioral deficits in a rat model of neurotoxicity induced by 6-hydroxydopamine (6-OHDA) and to investigate insulin-like growth factor 1 (IGF-1) potential therapeutic effects on these pathological markers. Methods: Behavioral changes were evaluated in male Wistar rats at 1, 2, and 3 weeks post-lesion using the elevated plus maze and dark–light box tests. Anxiety-like behaviors emerged as early as week 1 post-lesion and persisted through week 3. Following 6-OHDA infusion, immunohistochemical analysis revealed a decrease in tyrosine hydroxylase (TH) immunoreactivity within the ventral tegmental area (VTA) indicating a partial lesion of the nigrostriatal dopaminergic system. As a therapeutic approach we performed the intracisternal administration of a recombinant adenoviral vector encoding IGF-1 (RAd IGF-1) one week after 6-OHDA-induced neurotoxicity. Results: At a behavioral level, IGF-1 treatment effectively prevented anxiety-like behavior by the third week of neurotoxicity. Nevertheless, IGF-1 overexpression was not able to modulate VTA dopaminergic neuron loss. These results reveal a dissociation between the behavioral effects of IGF-1 and its impact on dopaminergic neurodegeneration. Discussion: These findings emphasize time-dependent alterations in anxiety-like behavior and dopaminergic neurodegeneration. In addition, these data support the potential use of IGF-1 as a therapeutic molecule and its novel administrations for future gene transfer interventions, which will shed light on the progressive nature of neurodegenerative mechanisms.

16 July 2022
Verified
Journal Article
Closed access
Aracely Janneth Naranjo ViteriAracely Janneth Naranjo Viteri
Aracely Janneth Naranjo Viteri
GCGalo Alberto Insuasti Castelo
Galo Alberto Insuasti Castelo
VFVioleta Maricela Dalgo Flores
Violeta Maricela Dalgo Flores